登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，4月6日，Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-04-07

  • Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy

    Jeffrey D. Jensen & Michael Lynch

    Heredity (2020)

    With the rapid global spread of SARS-CoV-2, tremendous efforts have been focused upon potential treatment strategies (Li and De Clercq 2020). Evolutionary theory has an important role to play in this search, and we here discuss one potentially under-appreciated research avenue.

  • 原文来源：https://www.nature.com/articles/s41437-020-0314-z
22浏览量
原文链接
相关报告

  • 《Nature，5月4日，A human monoclonal antibody blocking SARS-CoV-2 infection》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-05
    • A human monoclonal antibody blocking SARS-CoV-2 infection Chunyan Wang, Wentao Li, Dubravka Drabek, Nisreen M. A. Okba, Rien van Haperen, Albert D. M. E. Osterhaus, Frank J. M. van Kuppeveld, Bart L. Haagmans, Frank Grosveld & Berend-Jan Bosch Nature Communications volume 11, Article number: 2251 (2020) Abstract The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.
    298浏览量
    原文链接

  • 《Nature，6月9日，Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-06-10
    • Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic Rodrigo Jácome, José Alberto Campillo-Balderas, Samuel Ponce de León, Arturo Becerra & Antonio Lazcano Scientific Reports volume 10, Article number: 9294 (2020) Abstract As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens.
    154浏览量
    原文链接